News & Updates

Lower plasma ACE2 levels may partially mediate COVID-19 risks in overweight/obesity or low socioeconomic position
Lower plasma ACE2 levels may partially mediate COVID-19 risks in overweight/obesity or low socioeconomic position
10 Jan 2023 bySarah Cheung

Lower plasma angiotensin-converting enzyme 2 (ACE2) levels may partially mediate COVID-19 risks in individuals with overweight/obesity or low socioeconomic position (SEP; referring to low educational attainment), according to a large-scale Mendelian randomization study conducted by researchers at the University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK).

Lower plasma ACE2 levels may partially mediate COVID-19 risks in overweight/obesity or low socioeconomic position
10 Jan 2023
Parkinson’s, T2D drug affords cardioprotection in youth with T1D
Parkinson’s, T2D drug affords cardioprotection in youth with T1D
31 Dec 2022 byJairia Dela Cruz

Bromocriptine quick release, a medication used for Parkinson’s disease and type 2 diabetes (T2D), appears to confer cardiovascular benefits such as lower blood pressure (BP) and reduced aortic stiffness in teenagers with type 1 diabetes (T1D), according to data from the BCQR-T1D study.

Parkinson’s, T2D drug affords cardioprotection in youth with T1D
31 Dec 2022
Neutrophil-to-lymphocyte ratio predicts ischaemic stroke in Chinese T2DM patients
Neutrophil-to-lymphocyte ratio predicts ischaemic stroke in Chinese T2DM patients
29 Dec 2022